Randomised, placebo-controlled trial of dexamethasone for quality of life in pulmonary sarcoidosis

Vis, Roeland; Garde, E.M.W. van de; Meek, Bob; Korenromp, Ingrid H.E.; Grutters, Jan C.

doi:10.1016/j.rmed.2020.105936

Cited by 18 publications

(6 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Small fiber neuropathy relates to many diseases, is characterized by debilitating neuropathic symptoms—mainly pain and dysautonomia—and occurs in up to 60% of sarcoidosis patients. 93 Often under-recognized, diagnosis requires large fiber disease exclusion and is facilitated by skin biopsy and sudomotor testing. 94 Since there is no established treatment, palliative treatment on a case-by-case basis may include tramadol, anticonvulsants, topiramate, gamma-aminobutyric acid analogues, and intravenous immunoglobulin.…”

Section: Specific Considerationsmentioning

confidence: 99%

State-of-the-Art Treatments for Sarcoidosis

Papanikolaou¹,

Antonakis²,

Pandi³

2022

Methodist DeBakey Cardiovascular Journal

View full text Add to dashboard Cite

Sarcoidosis is a heterogeneous disease with various treatment indications. Although it affects mainly the lungs, sarcoidosis can affect every organ, especially when the disease course is chronic and protracted. Regular patient follow-up is recommended for early recognition of active, ongoing organ-specific granulomatous inflammation to avoid progression to irreversible fibrosis. In this review, we elaborate on treatment indications and various anti-sarcoidosis regimens proven useful in clinical trials. We also review specialized treatment of specific disease manifestations, with a focus on cardiac sarcoidosis. We also report on treatment for special conditions such as fatigue and small fiber neuropathy. Treatment for sarcoidosis is an emerging landscape, with new data complementing the existing knowledge.

show abstract

Section: Specific Considerationsmentioning

confidence: 99%

State-of-the-Art Treatments for Sarcoidosis

Papanikolaou¹,

Antonakis²,

Pandi³

2022

Methodist DeBakey Cardiovascular Journal

View full text Add to dashboard Cite

show abstract

“…[ 86 ]. Importantly, corticosteroids have a dose-dependent negative impact on quality of life [ 87 , 88 ]. The trend is to use second-line treatments as soon as possible as corticosteroid-sparing agents to limit adverse events of corticosteroids, as recommended for rheumatoid arthritis.…”

Section: Care Of Patients With Extrapulmonary Sarcoidosismentioning

confidence: 99%

How to Tackle the Diagnosis and Treatment in the Diverse Scenarios of Extrapulmonary Sarcoidosis

et al. 2021

View full text Add to dashboard Cite

Extrapulmonary sarcoidosis occurs in 30-50% of cases of sarcoidosis, most often in association with pulmonary involvement, and virtually any organ can be involved. Its incidence depends according to the organs considered, clinical phenotype, and history of sarcoidosis, but also on epidemiological factors like age, sex, geographic ancestry, and socio-professional factors. The presentation, symptomatology, organ dysfunction, severity, and lethal risk vary from and to patient even at the level of the same organ. The presentation may be specific or not, and its occurrence is at variable times in the history of sarcoidosis from initial to delayed. There are

show abstract

“…При лечении дексаметазоном были выявлены существенные улучшения в подшкалах SF-36 «жизнеспособность» и «боль», а также снижение содержания кортизола в сыворотке крови, АПФ и уровня растворимого рецептора интерлейкина-2. Низкие дозы дексаметазона уменьшали воспаление, улучшали качество жизни, снижали усталость [58].…”

Section: малоинвазивная диагностикаunclassified

Sarcoidosis in the Proceedings of European (Paris) and Russian (Moscow) Respiratory Congresses From 2018

Визель¹,

Визель²,

AMIROV³

et al. 2019

BCCM

View full text Add to dashboard Cite

28. Rukovodstvo Nacional'noj akademii klinicheskoj biohimii po laboratornoj medicinskoj praktike ispol'zovaniya biohimicheskih markerov pri OKS i SN [Guidelines of the National Academy of clinical biochemistry on laboratory medical practice of using biochemical markers in ACS and CH]. Laboratornaya diagnostika [Laboratory diagnostics]. 2008; 1 (17): 13-32. 29. Belen'kova YuA, Kashtalap VV, Karetnikova VN et al. Faktory vospaleniya, vliyayushchie na prognoz u bol'nyh infarktom miokarda s pod"emom segmenta ST, podvergshihsya chreskozhnym koronarnym [Factors of inflammation affecting the prognosis in patients with myocardial infarction with ST-segment elevation subjected to percutaneous coronary]. Kardioangiologii [Cardioangiologies]. 2012; 29: 51-58. 30. Degtyareva OV, Petyunina OV. Syvorotochnyj neopterin i S reaktivnyj belok u bol'nyh s raznymi klinicheskimi variantami ostrogo koronarnogo [Serum neopterin and C reactive protein in patients with different clinical variants of acute coronary]. Ukr Terapevt Zhurnal [Ukr Therapist Sib]. 2008; 1: 41-44.

show abstract

Randomised, placebo-controlled trial of dexamethasone for quality of life in pulmonary sarcoidosis

Cited by 18 publications

References 34 publications

State-of-the-Art Treatments for Sarcoidosis

State-of-the-Art Treatments for Sarcoidosis

How to Tackle the Diagnosis and Treatment in the Diverse Scenarios of Extrapulmonary Sarcoidosis

Sarcoidosis in the Proceedings of European (Paris) and Russian (Moscow) Respiratory Congresses From 2018

Contact Info

Product

Resources

About